Tracking Plasma Biomarkers in Alzheimer's Disease

Evaluating plasma biomarkers in Alzheimer's disease represents a transformative milestone for neurodegenerative clinical medicine. Monoclonal antibodies targeting amyloid-beta aggregates, such as lecanemab, slow cognitive decline in individuals with early symptomatic dementia. However, clinicians face persistent challenges when monitoring individual therapeutic response in routine outpatient practice. While amyloid positron emission tomography and lumbar punctures offer definitive evidence of plaque removal, both modalities remain expensive, invasive, and logistically burdensome. Consequently, peripheral blood diagnostics provide an accessible, scalable alternative for routine longitudinal monitoring during therapy. Recent multicenter evidence demonstrates that monoclonal antibody administration initiates broad downstream proteomic alterations across several biological systems. Peripheral blood captures dynamic changes reflecting cortical amyloid clearance, reactive astrogliosis, microglial activation, and synaptic preservation over time. Furthermore, tracking these circulating protein trajectories helps clinicians distinguish active biological plaque removal from progressive downstream neurodegeneration. Understanding these dynamic molecular alterations enables neurologists to optimize patient selection, monitor therapeutic engagement, and tailor treatment duration safely. Therefore, blood-based biomarker profiling promises to transform empirical Alzheimer's management into biochemically guided, personalized clinical neurology.

Real-World Longitudinal Study Design and Patient Cohorts

To evaluate these proteomic dynamics, investigators conducted a longitudinal cohort study at Washington University in St. Louis. The primary research objective involved characterizing longitudinal alterations across 130 plasma proteins among patients receiving regular lecanemab infusions. The intervention cohort comprised 197 individuals diagnosed with early symptomatic Alzheimer's disease exhibiting biomarker-confirmed amyloid pathology. Participants received intravenous lecanemab infusions at 10 mg/kg every two weeks over a two-year evaluation period. Patients underwent standardized clinical assessments and blood draws approximately every six months throughout active treatment. Additionally, investigators established two well-characterized comparator cohorts to distinguish treatment effects from natural disease progression. The untreated control group included 1,312 participants, combining prospective infusion candidates with longitudinal observational research subjects. Concurrently, 458 amyloid-negative, cognitively unimpaired individuals provided healthy biological reference ranges for all analyzed plasma proteins. Researchers quantified plasma concentrations using high-sensitivity multiplexed proteomic assays and multivariable mixed-effects regression models. Consequently, this rigorous methodological design isolated drug-induced molecular shifts from age-associated neurodegeneration, ensuring robust clinical findings.

Four Divergent Trajectories of Plasma Proteomic Markers

High-throughput proteomic profiling revealed that 34 of the 130 evaluated plasma proteins changed significantly following biweekly lecanemab administration. Interestingly, statistical clustering separated these responsive proteins into four distinct biological trajectories: normalising, overcorrecting, opposite, and unchanged. The normalising trajectory featured established hallmarks of Alzheimer's pathology, including phosphorylated tau species like p-tau217 and glial fibrillary acidic protein. These markers steadily declined toward concentrations typical of amyloid-negative healthy controls, reflecting reduced amyloid burden and subdued astrocytic activation. In contrast, circulating amyloid-beta peptides exhibited an overcorrecting trajectory, rising sharply and exceeding concentrations observed in unimpaired individuals. Meanwhile, synaptic and microglial proteins, including neurogranin, neuronal pentraxin receptor, and soluble TREM2, followed an opposite trajectory. Specifically, these inflammatory and synaptic mediators diverged further away from healthy benchmarks throughout the entire treatment course. Finally, critical structural proteins like neurofilament light chain and apolipoprotein E remained largely stable across the study interval. Therefore, these divergent trajectories prove that anti-amyloid therapy elicits complex, multi-system biological responses rather than uniform systemic normalization.

Mechanistic Insights: Amyloid Clearance Versus Glial Activation

These divergent biomarker patterns provide critical mechanistic insights into the cellular cascades governing therapeutic amyloid clearance in living patients. Specifically, the prompt decrease in plasma p-tau217 correlates tightly with the disaggregation of toxic amyloid aggregates within brain parenchyma. As monoclonal antibodies clear fibrillar plaques, downstream neuronal tau hyperphosphorylation abates rapidly, signaling meaningful biochemical interruption of disease pathogenesis. Conversely, the significant elevation of soluble TREM2 reflects robust microglial activation rather than unmitigated tissue destruction. Brain microglia actively phagocytose antibody-opsonized plaques, generating a pronounced neuroinflammatory signature during active clearance phases. However, persistent abnormalities in synaptic proteins like neurogranin indicate that synaptic repair and dendritic recovery lag behind plaque removal. Furthermore, the stability of neurofilament light chain suggests that axonal restoration requires prolonged monitoring before showing detectable reductions. Thus, biomarker dynamics reveal an asynchronous recovery timeline across different neurobiological domains. Plaque clearance triggers immediate biochemical improvements, whereas cellular and synaptic healing demands continued therapeutic management and neuroprotective support.

Clinical Implications and Future Diagnostic Monitoring

The discovery of distinct plasma trajectories introduces transformative opportunities for routine clinical neurology and outpatient dementia management. Currently, clinicians rely heavily on serial positron emission tomography to evaluate therapeutic clearance, which imposes substantial economic and logistical barriers. In contrast, serial assessment of plasma p-tau217 offers a rapid, minimally invasive approach to verify biological target engagement. Clinicians can determine when individuals reach amyloid negativity, enabling objective discussions regarding dosing frequency or maintenance strategies. Furthermore, baseline concentrations of synaptic and inflammatory proteins independently predicted the rate of subsequent cognitive change. Consequently, multiplexed plasma panels may soon provide dual clinical utility by measuring treatment efficacy while establishing individual patient prognosis. Additionally, accessible blood testing facilitates broader clinical adoption in developing healthcare systems where specialized radiotracers remain scarce. As assay standardization advances, these dynamic blood-based biomarkers will guide personalized therapeutic decisions and enhance long-term outcomes in Alzheimer's disease.

Perspectives on Global Implementation and Indian Healthcare

The advent of accessible blood-based biomarkers offers compelling advantages for expanding dementia care in resource-constrained environments like India. While novel monoclonal antibodies face regulatory, infrastructure, and financial hurdles before widespread adoption, diagnostic biomarker assays hold immediate clinical promise. In India, advanced molecular imaging facilities equipped with dedicated amyloid radiotracers remain concentrated in Tier-1 metropolitan centers, limiting nationwide accessibility. Conversely, standardized plasma biomarker assays require simple venipuncture and centralized laboratory processing, dramatically expanding specialized diagnostic access across diverse healthcare tiers. Furthermore, accurate baseline plasma profiling empowers neurologists and geriatricians to distinguish Alzheimer's disease from vascular cognitive impairment with greater precision. As domestic clinical research advances, validating diagnostic cutoffs across ethnically diverse Indian cohorts will remain essential. Additionally, clinicians must counsel families thoughtfully, clarifying that biochemical plaque clearance precedes tangible cognitive stabilization. Ultimately, integrating high-sensitivity plasma biomarkers into clinical workflows will streamline early diagnosis, optimize therapeutic monitoring, and prepare healthcare systems for modern disease-modifying dementia therapeutics.

Frequently Asked Questions

How does lecanemab influence plasma p-tau217 and glial fibrillary acidic protein levels?

Lecanemab therapy induces significant decreases in plasma phosphorylated tau 217 and glial fibrillary acidic protein concentrations over time. These reductions shift biomarker levels toward those observed in cognitively normal individuals lacking amyloid pathology, reflecting rapid clearance of cortical amyloid plaques and a concurrent reduction in reactive astrogliosis throughout the brain.

Why do microglial and synaptic markers follow trajectories opposite to amyloid clearance?

Proteins like soluble TREM2 rise during therapy because microglia actively engage in phagocytosing antibody-bound amyloid plaques. Concurrently, synaptic markers like neurogranin diverge because synaptic healing and circuit repair require extended time. These divergent trajectories demonstrate that neuroinflammatory clearance mechanisms precede neuronal and synaptic recovery during anti-amyloid treatment.

Can plasma biomarkers currently replace amyloid PET scans for clinical monitoring?

Plasma biomarkers show substantial promise for monitoring treatment response, but they cannot yet fully replace neuroimaging in routine clinical protocols. While reductions in p-tau217 strongly correlate with amyloid clearance, comprehensive clinical guidelines and international regulatory approvals still require standardized assay validation and rigorous cross-platform verification before replacing serial scans.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Mu R et al. Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study. Lancet Neurol. 2026 Nov. doi: 10.1016/S1474-4422(26)00284-X. PMID: 42785333.


2. van Dyck CH et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. doi: 10.1056/NEJMoa2212948. PMID: 36449413.


3. Ashton NJ et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. 2024;81(3):255-263. doi: 10.1001/jamaneurol.2023.5319. PMID: 38252443.